Abstract submissions are open from June 1 and will be accepted until October 8, 2026 (18:00 Dubai time, GMT+4).
You are invited to submit abstracts for the Eleventh MENACTRIMS Congress, to be held in Dubai, United Arab Emirates, during December 4–5, 2026. Abstract submissions will open on June 1, 2026, and will remain possible until October 8, 2026 (18:00 Dubai time, GMT+4). Depending on the number and quality of submitted abstracts, abstracts will be selected for either platform or poster presentation.
Abstracts can be re-edited and modified until the submission deadline. Any abstract received after the deadline will not be accepted. Upon completion of evaluation an ‘Accepted’ or ‘Rejected’ email will be sent to each application submitted. Abstracts status will be sent out maximum by November 10.
Abstracts can be re-edited and modified until the submission deadline. Any abstract received after the deadline will not be accepted. Upon completion of evaluation an ‘Accepted’ or ‘Rejected’ email will be sent to each application submitted.
Abstracts status will be sent out maximum by November 10. Please look for an email in your email addresses used to submit from abstracts@lumina.ae.
All accepted abstracts will be published in the Multiple Sclerosis and Related Disorders Journal.
Abstract Submission Guidelines for Authors
Please review the following guidelines carefully before submitting your abstract. All submissions must comply with the scientific, ethical, formatting, and presentation requirements outlined below.
General Submission Guidelines
- All abstracts must be submitted electronically through the official MENACTRIMS abstract submission portal. Abstracts submitted by email, fax, or other means will not be accepted.
- Abstracts must be written in clear English using American English spelling.
- The submitting author is responsible for the scientific content, grammar, accuracy, and completeness of the submitted abstract.
- The submitting author must confirm that all co-authors have reviewed and approved the submitted abstract prior to submission.
- The presenting author must be listed among the co-authors and must not be affiliated primarily with industry.
- The presenting author of an accepted abstract is required to register for and attend the congress.
- Duplicate submissions are strictly prohibited. Authors may not submit multiple abstracts derived from the same study or dataset with only minor modifications to title, scope, sample size, or analysis.
- Previously published abstracts or abstracts presented at other international congresses may only be submitted if new data are included.
- Case reports are generally discouraged and will only be considered if they provide highly novel clinical insights or substantial educational value.
- Abstracts exceeding the permitted character limit or failing to comply with formatting requirements may be rejected without review.
Abstract Categories
Authors must select one primary category during submission:
- Clinical Aspects of MS
- Imaging and Non-imaging Biomarkers
- Diagnosis and Differential Diagnosis
- Epidemiology and Genetics
- Pathology and Pathogenesis of MS
- Quality of Life
- Therapy: Disease Modifying
- Therapy: Symptomatic
- Progressive MS
- Pediatric MS
- NMOSD and MOGAD
Title Instructions
- Titles must be concise, specific, and scientifically informative.
- Titles should be submitted in Title Case.
- Abbreviations are not permitted in the title unless universally recognized, such as MS or MRI.
- Titles may not exceed 250 characters including spaces.
Author Information
- Full names of all authors and co-authors must be provided during submission.
- Institutional affiliations, city, and country must be included for all authors.
- The presenting author must be clearly identified during submission.
- A maximum of 40 authors, including the presenting author, may be listed per abstract submission.
- The presenting author must be one of the listed co-authors and must disclose all relevant conflicts of interest.
Abstract Structure and Formatting
Character Limit: The full abstract text may not exceed 2,550 characters, including spaces and section headings, excluding title, author information, affiliations, and disclosures.
Required Sections
- Background: Brief context and rationale for the study.
- Objectives: Clear statement of the study aims or hypotheses.
- Methods: Description of study design, population, interventions, statistical analyses, and ethical approvals where applicable.
- Results: Presentation of key findings with sufficient supporting data.
- Conclusions: Summary of major findings and implications for research or clinical practice.
Formatting Instructions
- Use generic drug names only.
- Define all abbreviations at first mention except universally accepted abbreviations such as MS or MRI.
- Avoid excessive use of abbreviations.
- Greek letters, mathematical symbols, and special formatting should be inserted using the submission platform tools.
- Do NOT include references within the abstract text.
- Commercial product names should not appear in titles.
- Tables, figures, graphs, and images are NOT permitted in submitted abstracts and will be automatically removed if included.
Ethical Considerations
- Studies involving human participants must comply with international ethical standards and institutional review board requirements.
- Authors should confirm that informed consent was obtained where appropriate.
- Patient confidentiality must be strictly maintained. No identifiable patient information should appear in abstracts.
- Animal studies must comply with institutional and international ethical standards.
- The Scientific Committee reserves the right to reject abstracts that do not meet ethical standards.
Funding and Disclosures
- All funding sources and research support must be disclosed during submission.
- Authors must disclose any potential conflicts of interest related to the submitted work.
- Disclosure information may be published alongside accepted abstracts.
- Failure to disclose relevant financial relationships may result in rejection or withdrawal of the abstract.
Review Process
- All abstracts will undergo blinded peer review by the MENACTRIMS Scientific Committee.
- Reviewers will evaluate abstracts based on scientific merit, originality, clinical relevance, methodological quality, statistical rigor, clarity of presentation, relevance to the congress themes, and overall impact.
- The Scientific Committee reserves the right to accept abstracts as oral or poster presentations, reassign categories, or reject abstracts not meeting scientific or ethical standards.
- Decisions of the Scientific Committee are final.
- The presenting author should confirm attendance within one week of receiving the acceptance email.
- To withdraw an abstract, a written statement listing the reasons must be sent to abstracts@lumina.ae.
Poster Design
Accepted poster presenters are not required to upload their posters during the abstract submission phase. Authors are responsible for printing and bringing their posters to the congress venue.
Poster Dimensions: Width: 90 cm / Height: 150 cm
Poster Preparation Instructions
- Authors are required to use the official MENACTRIMS poster template available in the Presentation Templates section below.
- The poster background and template design must not be altered.
- Authors should not add poster numbers or poster codes to their posters.
- Ushers and congress staff will be available onsite to assist authors with mounting their posters.
- Posters should be mounted and removed according to the timings communicated in the final congress program.
Oral Presentation Guidelines
- The same abstract title and topic accepted by the Scientific Committee must be presented during the congress.
- Oral presentations will consist of 8 minutes presentation and 2 minutes discussion/questions.
- Oral presenters must submit their final PowerPoint presentation and short biography no later than 6 days prior to the congress to nchahwan@lumina.ae.
- The email subject should follow this format: MSC2026-Presentation-OCX.X. Example: MSC2026-Presentation-OC2.2.
- Delayed presentation submission may result in removal from the oral presentation program.
- Presenting authors should be present in their designated hall at least 15 minutes before the start of their session.
- All presentations must be prepared in Microsoft Office PowerPoint format.
- Presenters are required to bring their presentations on duplicate storage media.
- Personal laptops and MAC devices may not be used unless approved in advance by the technical team.
- If presenters fail to send their presentations before the deadline, they must report early for uploading and testing onsite.
Presentation Templates
Oral Presentation Template: Oral presentations should follow the official MENACTRIMS oral presentation template.
Poster Template: Poster presentations should follow the official MENACTRIMS poster presentation template.
Authors must select one primary category during submission:
- Clinical Aspects of MS
- Imaging and Non-imaging Biomarkers
- Diagnosis and Differential Diagnosis
- Epidemiology and Genetics
- Pathology and Pathogenesis of MS
- Quality of Life
- Therapy: Disease Modifying
- Therapy: Symptomatic
- Progressive MS
- Pediatric MS
- NMOSD and MOGAD
- The same abstract and title submission indicated in this email need to be used during the congress and not another topic can fill your currently accepted slot.
- Oral presentations will be for a maximum of 8 minutes with 2 minutes for questions/comments.
- Oral presenters need to send their power point presentation 6 days prior to the congress along with their biographies to nchahwan@lumina.ae with Subject: MSC2026-Presentation-OCX.X example: MSC2026-Presentation-OC2.2. Any delay in delivering this presentation does not guarantee the oral slot in the program.
- Presenting authors should be present at their designated hall 15 minutes before the start of the session in which they will present to ensure enough time to mount their presentations for electronic projection.
- All presentations should be made available in Microsoft Office Power point in a flash USB disk drive or CD. Speakers may not use your own laptop nor use a MAC version. Please ensure the presentation available in duplicate media to prevent bad surprises on the day.
- Presenting authors should be present at their designated hall 15 minutes before the start of the session in which they will present to ensure enough time to mount their presentations for electronic projection in case they do not send it beforehand.
POSTER DESIGN
Accepted posters (you do not need to upload your poster during the submission phase) need to print their own posters in the precise dimensions mentioned in this section:
- Width: 90cm
- Height: 150cm
Please use the template found on this page to prepare your poster presentation. Please do not alter the PPT background when designing your poster nor add your poster to it. The organizers will add the poster code on each board, facilitating identification of where to place your poster during the event. Ushers will be available to assist authors in mounting their posters on their poster.
ORAL PRESENTATION TEMPLATE
Presentations will be for a maximum of 8 minutes with 2 minutes for questions/comments.
Please download the Oral presentation template found below:
- All abstracts must be submitted electronically through the official MENACTRIMS abstract submission portal. Abstracts submitted by email, fax, or other means will not be accepted.
- Abstracts must be written in clear English using American English spelling.
- The submitting author is responsible for the scientific content, grammar, accuracy, and completeness of the submitted abstract.
- The submitting author must confirm that all co-authors have reviewed and approved the submitted abstract prior to submission.
- The presenting author must be listed among the co-authors and must not be affiliated primarily with industry.
- The presenting author of an accepted abstract is required to register for and attend the congress.
- Duplicate submissions are strictly prohibited. Authors may not submit multiple abstracts derived from the same study or dataset with only minor modifications to title, scope, sample size, or analysis. The Scientific Committee reserves the right to reject duplicate submissions at any stage of the review process or after presentation if duplication is identified.
- Previously published abstracts or abstracts presented at other international congresses may only be submitted if new data are included.
- Case reports are generally discouraged and will only be considered if they provide highly novel clinical insights or substantial educational value.
- Abstracts exceeding the permitted character limit or failing to comply with formatting requirements may be rejected without review.
CO-AUTHOR APPROVAL
The submitting author must verify that all co-authors have read and approved the submission of the abstract.
ACCEPTANCE & REJECTION
Abstracts will be reviewed blinded without the names of submitting authors appearing to the reviewers.
The reviewers will judge the abstracts according to the scientific or clinical value, relevance to the conference, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English, and overall impression.
Upon completion of the evaluation of submitted abstracts, an ‘Accepted’ or ‘Rejected’ email will be sent to authors. Abstract acceptance will be in poster presentation. Upon acceptance of an author’s submission, the following instructions below are applicable:
- The presenting author of the presentation should confirm their attendance upon receiving the acceptance email within one week.
- If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the abstract helpdesk at abstracts@lumina.ae.